Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.
One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.
Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.
Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.
Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.
For further information about Microbot Medical, please visit www.microbotmedical.com.
Microbot Medical Inc. (NASDAQ: MBOT) announced a significant milestone in its collaboration with Corewell Health™ on robotic telesurgery for endovascular applications. Research demonstrating the feasibility of using the LIBERTY® Endovascular Robotic System between separate facilities 5 miles apart in a coronary simulation model has been accepted for presentation at the Cardiovascular Research Technologies (CRT) annual meeting on March 10, 2025.
The study, led by Dr. Ryan Madder, Section Chief of Interventional Cardiology at Corewell Health™, will be presented by Dr. Trisha Gomez and published in the Journal of the American College of Cardiology (JACC) Interventions. Dr. Madder noted that the LIBERTY® system "functioned well in a telerobotic setting" with its small footprint and disposable design creating "exciting possibilities for future telerobotic endovascular procedures."
Microbot's CEO Harel Gadot emphasized that telesurgery capabilities are an important part of their long-term strategy, potentially increasing access to quality healthcare for patients in remote locations. The telesurgery feature is still under development and not covered under Microbot's pending 510(k) submission with the FDA.
Microbot Medical (MBOT) has successfully closed a registered direct offering, raising $13 million through the sale of 6,103,289 common stock shares at $2.13 per share. The company also issued unregistered short-term series I preferred investment options in a concurrent private placement, allowing the purchase of up to 12,206,578 additional shares at $2.13 per share, exercisable for two years following stockholder approval.
The net proceeds will fund the development, commercialization, and regulatory activities for the LIBERTY® Robotic System, expand applications from the company's IP portfolio, and provide working capital. H.C. Wainwright & Co. served as the exclusive placement agent for the offerings.
Microbot Medical (Nasdaq: MBOT) has announced a $13 million registered direct offering priced at-the-market, selling 6,103,289 shares of common stock at $2.13 per share. The company is also conducting a concurrent private placement of unregistered short-term series I preferred investment options.
These investment options allow the purchase of up to 12,206,578 additional shares at $2.13 per share, exercisable for two years following stockholder approval. The closing is expected around February 11, 2025, with H.C. Wainwright & Co. serving as the exclusive placement agent.
The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital. The offering is made under a previously filed S-3 registration statement, while the preferred investment options are issued under Section 4(a)(2) of the Securities Act.
Microbot Medical (Nasdaq: MBOT) announced the acceptance of a late-breaking abstract for presentation at the Society of Interventional Radiology (SIR) annual meeting in Nashville from March 29 - April 2, 2025. The presentation will feature first-time data from the ACCESS-PVI trial, a prospective, multicenter, single-arm study evaluating the performance and safety of the LIBERTY® Endovascular Robotic System in peripheral vascular interventions.
The presentation titled 'Remote-controlled endovascular navigation with a miniature, single-use, robotic system. Results of the ACCESS-PVI trial' will be delivered by Dr. Francois Cornelis from Memorial Sloan Kettering Cancer Center on April 2, 2025. The company views this acceptance as significant since the conference attendees represent potential LIBERTY® system users.
Microbot Medical (Nasdaq: MBOT) has appointed Michal Ahuvia as Director of Operations to support the anticipated commercial launch of its LIBERTY® Endovascular Robotic System in Q2 2025. Ahuvia, who brings over 20 years of operations experience, will focus on ramping up production and improving efficiencies in preparation for commercialization.
Reporting to Simon Sharon, the Company's General Manager and Chief Technology Officer, Ahuvia will be responsible for strengthening manufacturing and operations processes. Her extensive background includes roles at Philips Healthcare, Nanomotion, XACT Robotics, and Jordan Valley, with expertise in process transformation, performance improvement, material planning, production, logistics, and supply chain management.
Microbot Medical (Nasdaq: MBOT) has elected David J. Wilson to its Board of Directors, strengthening its commercial capabilities as it prepares for the launch of the LIBERTY® Endovascular Robotic System. Wilson brings over 30 years of healthcare executive experience, including two decades at Johnson & Johnson where he served as Worldwide President of Cordis. He is currently CEO of InnovHeart and previously led Global Plasma at Haemonetics
The appointment aligns with Microbot's transition to a commercially focused organization, with the LIBERTY® system expected to launch in Q2 2025. Wilson replaces Yossi Bornstein, who served on the board since before the company went public in 2016. Wilson holds numerous medical device patents and has extensive experience in business strategy, R&D, and commercial product launches in the endovascular devices market.
Microbot Medical (Nasdaq: MBOT) has successfully closed its previously announced registered direct offering, raising $8.6 million in gross proceeds. The offering included 3,788,550 shares of common stock priced at $2.27 per share. Additionally, in a concurrent private placement, the company issued unregistered short-term series H preferred investment options to purchase up to 7,577,100 shares at $2.10 per share, exercisable immediately for two years.
The net proceeds will fund the continued development, commercialization, and regulatory activities for the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital. H.C. Wainwright & Co. served as the exclusive placement agent for the offerings.
Microbot Medical (MBOT) has announced a registered direct offering priced at-the-market, selling 3,788,550 shares of common stock at $2.27 per share. The company will also issue unregistered short-term series H preferred investment options in a concurrent private placement, allowing the purchase of up to 7,577,100 shares at $2.10 per share, exercisable for two years.
The offerings, expected to close around January 9, 2025, will generate approximately $8.6 million in gross proceeds. H.C. Wainwright & Co. serves as the exclusive placement agent. The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital for general corporate purposes.
Microbot Medical (Nasdaq: MBOT) has successfully raised approximately $11.8 million in gross proceeds through multiple offerings. The company completed a registered direct offering of 4,000,001 shares at $1.75 per share, generating about $7 million. Additionally, they issued unregistered short-term series G preferred investment options for up to 8,000,002 shares with an exercise price of $1.75, exercisable for two years.
The company also raised approximately $4.8 million through their at-the-market facility through January 2025. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from their IP portfolio, and provide working capital for general corporate purposes.
Microbot Medical (Nasdaq: MBOT) has announced a $7 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 4,000,002 shares of common stock at $1.75 per share. Additionally, in a concurrent private placement, Microbot will issue unregistered short-term series G preferred investment options to purchase up to 8,000,004 shares of common stock at an exercise price of $1.75 per share, exercisable for two years.
The closing is expected around January 7, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent. The proceeds will fund the development and commercialization of the LIBERTY® Robotic System, expand applications from existing IP portfolio, and provide working capital for general corporate purposes.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
What is Microbot Medical, Inc.?
What is the LIBERTY Endovascular Robotic Surgical System?
What recent achievements has Microbot Medical accomplished?
What are the core technologies developed by Microbot Medical?
What is the vision of Microbot Medical?
How is Microbot Medical preparing for commercialization?
What impact do recent geopolitical events have on Microbot Medical's operations?
What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?
Who is acting as the exclusive placement agent for Microbot Medical's offering?
How can I get more information about Microbot Medical?
